반려동물용 의료 시장 규모, 점유율, 동향 분석 : 동물별, 제품별, 유통 채널별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Companion Animal Health Market Summary

The global companion animal health market size was estimated at USD 25.46 billion in 2025 and is projected to reach USD 56.41 billion by 2033, growing at a CAGR of 10.6% from 2026 to 2033. The market is primarily driven by factors such as rapid advancements in the field of companion animal health, increase in zoonotic disease transfer from pets, evolving regulations, and rising R&D & procedural advancements.

Rapid innovation across therapeutics, diagnostics, and care delivery is transforming the companion animal health industry to resemble human healthcare in both complexity and value. Some of the advances in molecular biology, biologics, and formulation science enable targeted therapies that address specific disease pathways and support long-term disease management. Some of the regulatory actions, reflect growing acceptance of precision-driven veterinary medicines. For instance, the FDA, in April 2025, expanded treatment availability other than traditional pets by adding Faunamor to its Index of Legally Marketed Unapproved New Animal Drugs for Minor Species. Similarly, adoption of AI in diagnostics, regenerative medicine, and advanced referral infrastructure is improving clinical outcomes and operational efficiency.

The market is also driven by rising awareness of zoonotic diseases transmitted from pets to humans. As pets share indoor living spaces with families, risks associated with parasites, bacterial infections, and vector-borne diseases have moved into everyday public health conversations. Public health agencies such as the U.S. Centers for Disease Control and Prevention in their May 2025 publication highlighted that common pet-associated illnesses range from salmonellosis and ringworm to vector-borne infections transmitted through fleas and ticks, strengthening the need for preventive veterinary intervention at scale (CDC). This shift has incorporated preventive veterinary care such as routine vaccinations, parasite control, and regular screenings into standard pet ownership practices. Besides this, veterinarians emphasize year-round prevention and integrated wellness plans, driving recurring demand for pharmaceuticals, diagnostics, and vaccines.

Furthermore, evolving regulatory frameworks are playing a pivotal role in accelerating the growth of companion animal health industry by improving product approval efficiency, strengthening international cooperation, and modernizing outdated laws that historically slowed innovation. For instance, December 2025 updates from the U.S. FDA's Center for Veterinary Medicine (CVM) show a steady stream of approvals for new animal drugs, such as treatments for congestive heart failure and novel antiseptic formulations, which reflects regulators' willingness to evaluate and authorize important companion animal therapies in a timely manner. Similarly, industry groups adopt modernized regulatory pathways that reflect scientific complexity and innovation pace. A veterinary industry panel convened by the American Veterinary Medical Association in July 2025, highlighted the need for modernization of regulatory processes governing animal health products and nutrition, calling for enhancements in drug review efficiency and more agile frameworks that reflect the complexity of current innovations.

Global Companion Animal Health Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global companion animal health market report based on animal, product, distribution channel, end use and region:

• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Dogs
• Equine
• Cats
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Vaccines
• Pharmaceuticals
  • OTC
  • Prescription
• Feed Additives
• Diagnostics
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail
• E-commerce
• Hospital pharmacies
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Point-of-care/In-house testing
• Hospitals & clinics
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Animal
  • 1.2.2. Product
  • 1.2.3. Distribution Channel
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1 Analysis
  • 1.7.2. Model 2 Analysis
  • 1.7.3. Model 3 Analysis
• 1.8. List of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rapid Advancements in the Field of Companion Animal Health
    • 3.2.1.2. Increase In Zoonotic Disease Transfer from Pets
    • 3.2.1.3. Evolving Regulations
    • 3.2.1.4. Rising R&D & Procedural Advancements
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Development of Drug Resistance
    • 3.2.2.2. Emergence of Unverified Treatments
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
  • 3.2.5. Technology Landscape
• 3.3. Pricing Model Analysis
• 3.4. Product Pipeline/ Clinical Trial Analysis
• 3.5. Estimated Animal Population, By Key Countries, Key Species, 2025
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Companion Animal Health Market: By Animal Estimates & Trend Analysis

• 4.1. Companion Animal Health Market, By Animal: Segment Dashboard
• 4.2. Companion Animal Health Market, By Animal Movement Analysis
• 4.3. Companion Animal Health Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 4.4. Dogs
  • 4.4.1. Dogs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Equine
  • 4.5.1. Equine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Cats
  • 4.6.1. Cats Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Companion Animal Health Market: By Product Estimates & Trend Analysis

• 5.1. Companion Animal Health Market, By Product: Segment Dashboard
• 5.2. Companion Animal Health Market, By Product Movement Analysis
• 5.3. Companion Animal Health Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 5.4. Vaccines
  • 5.4.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Pharmaceuticals
  • 5.5.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. OTC
    • 5.5.2.1. OTC Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Prescription
    • 5.5.3.1. Prescription Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Feed Additives
  • 5.6.1. Feed Additives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Diagnostics
  • 5.7.1. Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Companion Animal Health Market: By Distribution Channel Estimates & Trend Analysis

• 6.1. Companion Animal Health Market, By Distribution Channel: Segment Dashboard
• 6.2. Companion Animal Health Market, By Distribution Channel Movement Analysis
• 6.3. Companion Animal Health Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
• 6.4. Retail
  • 6.4.1. Retail Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. E-commerce
  • 6.5.1. E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Hospital pharmacies
  • 6.6.1. Hospital pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Companion Animal Health Market: By End Use Estimates & Trend Analysis

• 7.1. Companion Animal Health Market, By End Use: Segment Dashboard
• 7.2. Companion Animal Health Market, By End Use Movement Analysis
• 7.3. Companion Animal Health Market Estimates & Forecasts, by End Use, 2021 to 2033 (USD Million)
• 7.4. Point-of-care/In-house testing
  • 7.4.1. Point-of-care/In-house testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Hospitals & clinics
  • 7.5.1. Hospitals & clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Companion Animal Health Market: By Regional Estimates & Trend Analysis

• 8.1. Region Market Dashboard
• 8.2. Region Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Position/Share Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Agrolabo S.p.A.
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product/Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Boehringer Ingelheim International GmbH
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product/Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Ceva
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product/Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Elanco
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product/Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. IDEXX Laboratories, Inc.
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product/Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Indian Immunologicals Ltd.
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product/Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Merck & Co., Inc.
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product/Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Norbrook
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product/Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Vetoquinol
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product/Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Virbac
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product/Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Zoetis Services LLC
    • 9.3.11.1. Participant's Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Product/Service Benchmarking
    • 9.3.11.4. Strategic Initiatives